News | March 25, 2026
ImmunityBio scores first Asian approval for ANKTIVA in Macau
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Subscribe To Our Newsletter & Stay Updated
